This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1299 entries already.
Now that US President Donald Trump has loudly announced his intention to withdraw from the Paris climate targets and refocus the US economy on fossil fuel production, Europe, which is still a leader in the bioeconomy, is sensing an opportunity. A new cluster alliance of 14 production sites wants to advance the high-tech bioeconomy.
Hair loss therapeutics developer Mallia Therapeutics and Northway Biotech have partners to set up a manufacturing process of soluble CD83 protein to prevent and cure hair loss.
Helsinki-based Aplagon has secured €7m in financing to advance its therapeutic APAC into Phase 2a clinical trials.
One day after presenting its competition strategy, the EU Commission has launched an EU Biotech and Biomanufacturing Hub. The collection of information is intended to help biotech start-ups navigate through the jungle of EU funding measures and provide access to networks that help with patenting, product authorisation and compliance with EU regulations.
Dutch venture capital firm Forbion revealed that its BioEconomy Fund I has amassed €164.5m. This surpasses the fund’s initial target of €150m, highlighting the increasing interest from investors in the commercial viability of biotech solutions that tackle worldwide sustainability issues.
The FDA has approved Novo Nordisk’s blockbuster drug Ozempic (semaglutide) for patients with chronic kidney disease who also have type 2 diabetes.
This year’s US$10,000 Innovation Award for the most relevant automation technology presentation at SLAS 2025 goes to Taci Pereira, CEO of Systemic Bio from Houston. She prevailed against nine finalists at the important automation conference SLAS 2025 in San Diego.
The British company Semarion Ltd and US start-ups n6 Tec Inc and Portal Biotechnologies Inc were honoured with the New Product Award at the SLAS Conference 2025 in San Diego. The award, presented by the Society for Automation & Drug Screening, recognises pioneering technologies with the potential to transform the industry.
Italian InSimili Srl has been awarded the Ignite Award for the most innovative start-up company in the lab automation sector. The US$5,000 prize was presented by the Society for Laboratory Automation and Screening (SLAS) to the company at SLAS 2025, the leading international conference for lab automation and drug screening
On the second day of SLAS 2025, the world’s largest laboratory automation conference in San Diego, the last two finalists of the Ignite Award pitched their business models. Meanwhile, the 10 finalists of the SLAS New Product Award showcased their systems in the Innovation AveNEW area of the exhibition.